Incyte Corporation – Wilmington, DE


Incyte’s new 190,000 square foot Global HQ on 16 acres in Wilmington Delaware.

Incyte, one of the nation’s most innovative companies, is best known as the developer and marketer of Jakafi, approved by the Food and Drug Administration in 2011 as a treatment for patients with intermediate or high-risk myelofibrosis, a group of rare cancers of the bone marrow. In 2014, the FDA also approved the drug as a treatment to patients with polycythemia vera, a slow-growing blood cancer that causes a person’s bone marrow to make too many red blood cells.
Read More “Incyte Corporation – Wilmington, DE”